Anti-angiogenic compositions and therapeutic applications thereof
AssigneeMedestea Research & Production S.p.A.
InventorsArnaldo CARUSO, Dario Di Luca
Life of this patent
Estimating the term…
Abstract
There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.
Claims13
1-12. (canceled)
A method for preventing or treating an angiogenesis and/or lymphangiogenesis-related disease, state or condition in a mammalian subject, comprising administering to the mammalian subject a therapeutically effective amount of a composition containing, alone or in combination:
- a) a HHV-6 nucleic acid molecule encoding a protein having anti-angiogenic and anti-lymphangiogenic activity, wherein said nucleic acid molecule has a sequence selected from:
- i) SEQ ID NO:1;
- ii) a sequence differing from SEQ ID NO:1 due to degeneracy of the genetic code;
- iii) a sequence which hybridizes to SEQ ID NO:1 under stringent conditions;
- b) an expression vector containing the nucleic acid molecule as above defined;
- c) a protein encoded by the nucleic acid molecule as above defined or an analogue thereof carrying conservative substitutions and retaining anti-angiogenic and anti-lymphangiogenic activity.
Dependencies are inferred from the claim text.